Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Angiotensin II
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Recipient : La Jolla Pharmaceutical
Deal Size : $132.0 million
Deal Type : Licensing Agreement
Details : La Jolla will get double-digit tiered royalty payments based on net sales of GIAPREZA and XERAVA. In exchange, La Jolla granted PAION an exclusive license to commercialize GIAPREZA and XERAVA in the Territories.
Product Name : Giapreza
Product Type : Peptide
Upfront Cash : $22.5 million
December 01, 2021
Lead Product(s) : Angiotensin II
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Recipient : La Jolla Pharmaceutical
Deal Size : $132.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Remimazolam Besylate
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Recipient : Acacia Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Investigation of Remimazolam in Children Undergoing Sedation for Medical Procedures
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
April 20, 2021
Lead Product(s) : Remimazolam Besylate
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Recipient : Acacia Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Remimazolam Besylate
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : University Medical Center Groningen | QPS Holdings
Deal Size : Inapplicable
Deal Type : Inapplicable
Assessment of the Pharmacodynamic and Pharmacokinetic Interaction of Remimazolam and Remifentanil
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 17, 2020
Lead Product(s) : Remimazolam Besylate
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : University Medical Center Groningen | QPS Holdings
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Remimazolam Besylate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Recipient : Nantes University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
November 02, 2020
Lead Product(s) : Remimazolam Besylate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Recipient : Nantes University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Remimazolam Besylate
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : PRA Health Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Oral Remimazolam With and Without Alcohol in Healthy Female Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
October 02, 2019
Lead Product(s) : Remimazolam Besylate
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : PRA Health Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Remimazolam Besylate
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : PRA Health Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Absolute Oral Bioavailability of Remimazolam
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
October 02, 2019
Lead Product(s) : Remimazolam Besylate
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : PRA Health Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Remimazolam Besylate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : PRA Health Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
October 01, 2019
Lead Product(s) : Remimazolam Besylate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : PRA Health Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Remimazolam Besylate
Therapeutic Area : Undisclosed
Study Phase : Phase III
Sponsor : ORION Clinical Services | Simbec Research | Creative Clinical Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
September 07, 2018
Lead Product(s) : Remimazolam Besylate
Therapeutic Area : Undisclosed
Highest Development Status : Phase III
Sponsor : ORION Clinical Services | Simbec Research | Creative Clinical Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Remimazolam Besylate
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : PRA Health Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
A Trial of Intranasal Remimazolam Pharmacokinetics, Pharmacodynamics, Safety and Bioavailability
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
November 01, 2017
Lead Product(s) : Remimazolam Besylate
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : PRA Health Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Remimazolam Besylate
Therapeutic Area : Undisclosed
Study Phase : Phase III
Sponsor : Premier Research Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy of Remimazolam in ASA III and IV Patients Undergoing Colonoscopy
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
August 26, 2015
Lead Product(s) : Remimazolam Besylate
Therapeutic Area : Undisclosed
Highest Development Status : Phase III
Sponsor : Premier Research Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
